Dr. Sasine on Predicting Individual Benefit with CAR T Cells

Joshua P. Sasine, MD, PhD
Published: Tuesday, Oct 08, 2019



Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies. 
 
Though it is difficult to pinpoint predictive patient characteristics to CAR T-cell therapy, it is getting easier, Sasine says. Both before and after CAR T-cell treatment, certain cytokine profiles appear to be associated with long-term, durable remissions.  
 
Also, characteristics of the treatment, such as the depth of lymphodepletion, could potentially indicate a patient’s prognosis. Importantly, this can be modified and controlled in the clinic, concludes Sasine. 
SELECTED
LANGUAGE


Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies. 
 
Though it is difficult to pinpoint predictive patient characteristics to CAR T-cell therapy, it is getting easier, Sasine says. Both before and after CAR T-cell treatment, certain cytokine profiles appear to be associated with long-term, durable remissions.  
 
Also, characteristics of the treatment, such as the depth of lymphodepletion, could potentially indicate a patient’s prognosis. Importantly, this can be modified and controlled in the clinic, concludes Sasine. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x